The latest lawsuit alleged Mylan violated a federal racketeering statute and various states’ consumer-protection laws by raising the EpiPen’s list price to give a share of the proceeds to pharmacy-benefit managers, or PBMs, and ensure the device was available for sale to patients.
…The prospects for such a lawsuit are unclear, since the theory of illegality underlying the claim hasn’t been litigated before.
Worth following this one.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”